Compound 49b Prevents Diabetes-induced Apoptosis Through Increased IGFBP-3 Levels

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2012 Apr 3

PMID 22467575

Citations 53

Authors

Qiuhua Zhang

Kimberly Guy

Jayaprakash Pagadala

Youde Jiang

Robert J Walker

Luhong Liu

Carl Soderland

Timothy S Kern

Robert Ferry Jr

Hui He

C Ryan Yates

Duane D Miller

Jena J Steinle

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine whether Compound 49b, a novel PKA-activating drug, can prevent diabetic-like changes in the rat retina through increased insulin-like growth factor binding protein-3 (IGFBP-3) levels.

Methods: For the cell culture studies, we used both human retinal endothelial cells (REC) and retinal Müller cells in either 5 mM (normal) or 25 mM (high) glucose. Cells were treated with 50 nM Compound 49b alone of following treatment with protein kinase A (PKA) siRNA or IGFBP-3 siRNA. Western blotting and ELISA analyses were done to verify PKA and IGFBP-3 knockdown, as well as to measure apoptotic markers. For animal studies, we used streptozotocin-treated rats after 2 and 8 months of diabetes. Some rats were treated topically with 1 mM Compound 49b. Analyses were done for retinal thickness, cell numbers in the ganglion cell layer, pericyte ghosts, and numbers of degenerate capillaries, as well as electroretinogram and heart morphology.

Results: Compound 49b requires active PKA and IGFBP-3 to prevent apoptosis of REC. Compound 49b significantly reduced the numbers of degenerate capillaries and pericyte ghosts, while preventing the decreased retinal thickness and loss of cells in the ganglion cell layer. Compound 49b maintained a normal electroretinogram, with no changes in blood pressure, intraocular pressure, or heart morphological changes.

Conclusions: Topical Compound 49b is able to prevent diabetic-like changes in the rat retina, without producing systemic changes. Compound 49b is able to prevent REC apoptosis through increasing IGFBP-3 levels, which are reduced in response to hyperglycemia.

Citing Articles

Semaphorin 7a regulates inflammatory mediators and permeability in retinal endothelial cells.

Liu L, Jiang Y, Steinle J Microvasc Res. 2023; 150:104587.

PMID: 37453650 PMC: 10528930. DOI: 10.1016/j.mvr.2023.104587.

Loss of cystatin C regulates permeability and inflammatory pathways in retina.

Liu L, Jiang Y, Steinle J Microvasc Res. 2023; 148:104510.

PMID: 36822364 PMC: 10258155. DOI: 10.1016/j.mvr.2023.104510.

The SIRT1-HMGB1 axis: Therapeutic potential to ameliorate inflammatory responses and tumor occurrence.

Wei L, Zhang W, Li Y, Zhai J Front Cell Dev Biol. 2022; 10:986511.

PMID: 36081910 PMC: 9448523. DOI: 10.3389/fcell.2022.986511.

TNFAIP3 is anti-inflammatory in the retinal vasculature.

Liu L, Jiang Y, Steinle J Mol Vis. 2022; 28:124-129.

PMID: 36034737 PMC: 9352365.

Advances in the study of RNA-binding proteins in diabetic complications.

Chen X, Wu J, Li Z, Han J, Xia P, Shen Y Mol Metab. 2022; 62:101515.

PMID: 35597446 PMC: 9168169. DOI: 10.1016/j.molmet.2022.101515.

References

Giannini S, Cresci B, Pala L, Ciucci A, Franchini A, Manuelli C . IGFBPs modulate IGF-I- and high glucose-controlled growth of human retinal endothelial cells. J Endocrinol. 2001; 171(2):273-84. DOI: 10.1677/joe.0.1710273. View

Kielczewski J, Jarajapu Y, McFarland E, Cai J, Afzal A, Li Calzi S . Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res. 2009; 105(9):897-905. PMC: 3635679. DOI: 10.1161/CIRCRESAHA.109.199059. View

Chang K, Chan-Ling T, McFarland E, Afzal A, Pan H, Baxter L . IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci U S A. 2007; 104(25):10595-600. PMC: 1965558. DOI: 10.1073/pnas.0702072104. View

Opreanu M, Tikhonenko M, Bozack S, Lydic T, Reid G, McSorley K . The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models. Diabetes. 2011; 60(9):2370-8. PMC: 3161322. DOI: 10.2337/db10-0550. View

Lofqvist C, Chen J, Connor K, Smith A, Aderman C, Liu N . IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A. 2007; 104(25):10589-94. PMC: 1965557. DOI: 10.1073/pnas.0702031104. View

ENGERMAN R, Kern T . Retinopathy in animal models of diabetes. Diabetes Metab Rev. 1995; 11(2):109-20. DOI: 10.1002/dmr.5610110203. View

Kern T, ENGERMAN R . Capillary lesions develop in retina rather than cerebral cortex in diabetes and experimental galactosemia. Arch Ophthalmol. 1996; 114(3):306-10. DOI: 10.1001/archopht.1996.01100130302013. View

Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G . Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J. 2004; 18(12):1456-8. DOI: 10.1096/fj.04-1618fje. View

Wichelhaus A, Russ M, Petersen S, Eckel J . G protein expression and adenylate cyclase regulation in ventricular cardiomyocytes from STZ-diabetic rats. Am J Physiol. 1994; 267(2 Pt 2):H548-55. DOI: 10.1152/ajpheart.1994.267.2.H548. View

10.

Steinle J, Kern T, Thomas S, McFadyen-Ketchum L, Smith C . Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice. Exp Eye Res. 2009; 88(6):1014-9. DOI: 10.1016/j.exer.2008.12.015. View

11.

Gardner T, Antonetti D, Barber A, LaNoue K, Levison S . Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2003; 47 Suppl 2:S253-62. DOI: 10.1016/s0039-6257(02)00387-9. View

12.

Kielczewski J, Hu P, Shaw L, Li Calzi S, Mames R, Gardiner T . Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury. Am J Pathol. 2011; 178(4):1517-28. PMC: 3078432. DOI: 10.1016/j.ajpath.2010.12.031. View

13.

Walker R, Steinle J . Role of beta-adrenergic receptors in inflammatory marker expression in Müller cells. Invest Ophthalmol Vis Sci. 2007; 48(11):5276-81. DOI: 10.1167/iovs.07-0129. View

14.

Kielczewski J, Li Calzi S, Shaw L, Cai J, Qi X, Ruan Q . Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Invest Ophthalmol Vis Sci. 2011; 52(11):8278-86. PMC: 3208060. DOI: 10.1167/iovs.11-8167. View

15.

Kern T, ENGERMAN R . Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res. 1994; 13(12):863-7. DOI: 10.3109/02713689409015087. View

16.

Conover C . Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism. Endocrinology. 1992; 130(6):3191-9. DOI: 10.1210/endo.130.6.1375895. View

17.

Han J, Jogie-Brahim S, Harada A, Oh Y . Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett. 2011; 307(2):200-10. DOI: 10.1016/j.canlet.2011.04.004. View

18.

Steinle J . Sympathetic neurotransmission modulates expression of inflammatory markers in the rat retina. Exp Eye Res. 2006; 84(1):118-25. DOI: 10.1016/j.exer.2006.09.006. View

19.

Calcutt N, Cooper M, Kern T, Schmidt A . Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov. 2009; 8(5):417-29. PMC: 7097138. DOI: 10.1038/nrd2476. View

20.

Jiang Y, Walker R, Kern T, Steinle J . Application of isoproterenol inhibits diabetic-like changes in the rat retina. Exp Eye Res. 2010; 91(2):171-9. PMC: 4319116. DOI: 10.1016/j.exer.2010.04.014. View